BACKGROUND: The FDA requirement for sensitivity of viral NAT methods used in blood screening is a 95‐percent detection limit of 100 copies per mL, whereas the NAT screening system should have a sensitivity of at least 5000 copies per mL per individual donation. According to the Common Technical Specifications of the European Directive 98/79/EC for in vitro diagnostics, viral standard dilutions (calibrated against the WHO standard) should be tested at least 24 times for a statistically valid assessment of the 95‐percent detection limit. STUDY DESIGN AND METHODS: Viral standard dilution panels (PeliCheck, VQC‐CLB) were prepared for HCV RNA genotypes 1 and 3 and for HIV RNA genotypes B and E. In a multicenter study, 23 laboratories tested the panels all together in 8 to 91 test runs per NAT method. RESULTS: The following 95‐percent detection limits (and 95% CIs) were found on the HCV RNA genotype 1 reference panels (shown as geq/mL): Gen‐Probe TMA, 85 (64‐118); AmpliScreen, 126 (83‐225); AmpliScreen with NucliSens Extractor, 21 (13‐44); Amplicor with NucliSens Extractor, 69 (50‐102), and Amplicor with Qiagen extraction technology, 144 (74‐102). On HIV RNA genotype B dilution panels, the following 95‐percent detection limits were found (shown as geq/mL): Gen‐Probe TMA, 31 (20‐52); AmpliScreen, 126 (67‐311); AmpliScreen with NucliSens Extractor, 37 (23‐69), and NucliSens QL assay, 123 (51‐566). HIV RNA genotype E panels were detected with equal sensitivity as HIV RNA genotype B panels. In the Gen‐Probe TMA assay, the 50‐percent detection limits on HIV RNA type B and type E were 3.6 (2.6‐5.0) and 3.9 (2.4‐5.8) geq per mL, respectively. The HCV RNA genotype 1 and 3 standards were detected with equal sensitivity. CONCLUSION: The differences in sensitivity between NAT assays can be explained by the input of isolated viral nucleic acid in the amplification reactions. The FDA requirements for sensitivity of NAT blood screening assays can be met by the Gen‐probe TMA, as well as by the AmpliScreen assays, particularly when combined with the NucliSens Extractor.
Transfusion – Wiley
Published: May 1, 2002
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera